Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (229) Apply Press releases filter
- Basic page (60) Apply Basic page filter
- Pipeline (26) Apply Pipeline filter
- Corporate presentations (24) Apply Corporate presentations filter
- Shareholder meeting (23) Apply Shareholder meeting filter
- Team member (23) Apply Team member filter
- Videos (16) Apply Videos filter
- Financial reports (12) Apply Financial reports filter
- Webcasts and audio (12) Apply Webcasts and audio filter
- Analyst (11) Apply Analyst filter
- Investor contact (6) Apply Investor contact filter
- Event (4) Apply Event filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
- Webform (1) Apply Webform filter
Oxford BioMedica Appoints Daniel Soland as Non-Executive Director to the Board
London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group
Oxford BioMedica Interim Management Statement
London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group” or “OXB”) (LSE:OXB), a leading gene and cell ther
Oxford BioMedica’s Phase I study results with RetinoStat® were selected as a “Hot Topic” at the Association for Research in Vision and Ophthalmology conference in US
Oxford, UK – 5 May 2015: Oxford BioMedica plc (LSE: OXB), (“the Company”) the leading gene and cell therapy based biopharmaceutica
Oxford BioMedica secures $50 million loan facility with Oberland Capital to support the Group's growth ambitions
Oxford, UK – 1 May 2015: Oxford BioMedica plc (LSE: OXB), (“Oxford BioMedica” or the “Group”) a leading gene and cell therapy Grou
Oxford BioMedica 2014 Annual Report and Accounts & AGM Notification
London, UK - 2 April 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy gro
Oxford BioMedica to Present at 3rd Annual Regen Med Investor Day
London, UK – 20 March 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy
2014 Preliminary Results Replay
You have selected Encore.